Top Institutional Investors

Caligan Partners LP — 13F Holdings & Portfolio

CIK 1727492 · latest 13F-HR filed 2026-08-14

Backtest portfolio

Caligan Partners LP manages $2.13B in 13F-reported U.S. long-equity assets across 28 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are LQDA (30.45%), RVMD (17.28%), ABVX (9.77%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 5 new positions and exited 4; 13 existing positions rose in reported value and 4 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$2.13B

Long-equity book

Holdings
28

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+5 / −4 / ↑13 / ↓4

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26
LQDA31.2% · 0%RVMD17.7% · +19%ABVX10.0% · +7%PCVX6.1% · +6%EXEL4.1% · 0%TNGX3.8% · +4%AVTX2.8% · +94%XENE2.6% · -36%ADMA2.3% · +20%LBRX2.3% · 0%IMCR2.1% · newVRDN1.9% · newVOR1.7% · 0%SABS1.5% · 0%IVA1.5% · +64%AURA1.5% · +1770%TYRA1.2% · -37%IRD1.2% · 0%ANIK1.0% · 0%SGMT0.9% · newARTV0.8% · newFTH0.8% · newMBX0.5% · -76%VRCA0.3% · 0%CLRB0.1% · new

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 82.9%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People
Assets Under Management
$1.30B
Discretionary
$1.30B
Employees
5
Accounts
8
Address
780 THIRD AVENUE
30TH FLOOR
NEW YORK, NY 10017
Phone
(646) 859-8204
Website
Name Title / Status Ownership Type
CALIGAN PARTNERS GP LLC ControlGENERAL PARTNERLess than 5%Domestic Entity
CROWLEY, TIFFANY ControlCHIEF FINANCIAL OFFICER/CHIEF COMPLIANCE OFFICERLess than 5%Individual
JOHNSON INVESTMENT TRUST ControlLIMITED PARTNER10–25%Domestic Entity
JOHNSON, DAVID, EDWARD ControlPARTNER / LIMITED PARTNER75% or moreIndividual
JOHNSON, DAVID, EDWARD ControlMEMBER75% or moreIndividual
JOHNSON, SARAH, BATES ControlTRUSTEEGeneral partnerIndividual
LAMAN, ROBERT, THOMAS ControlCHIEF OPERATING OFFICERLess than 5%Individual

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Caligan Partners LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 LIQUIDIA CORPORATION LQDA 53635D202 $647.3M 30.45% 8,118,892 SH
2 REVOLUTION MEDICINES INC RVMD 76155X100 $367.4M 17.28% 1,961,795 SH
3 ABIVAX SA ABVX 00370M103 $207.6M 9.77% 1,557,924 SH
4 VAXCYTE INC PCVX 92243G108 $127.2M 5.99% 2,188,636 SH
5 EXELIXIS INC EXEL 30161Q104 $84.5M 3.98% 1,553,262 SH
6 TANGO THERAPEUTICS INC TNGX 87583X109 $78.2M 3.68% 2,500,103 SH
7 AVALO THERAPEUTICS INC AVTX 05338F306 $58.5M 2.75% 3,163,866 SH
8 XENON PHARMACEUTICALS INC XENE 98420N105 $53.7M 2.53% 889,944 SH
9 ADMA BIOLOGICS INC ADMA 000899104 $47.9M 2.25% 5,725,007 SH
10 REVOLUTION MEDICINES INC Call RVMD 76155X100 $47.2M 2.22% 251,800 SH
11 LB PHARMACEUTICALS INC LBRX 50180M108 $46.7M 2.20% 1,438,070 SH
12 IMMUNOCORE HLDGS PLC IMCR 45258D105 $43.9M 2.06% 1,381,317 SH
13 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $40.3M 1.90% 2,193,981 SH
14 VOR BIOPHARMA INC VOR 929033207 $35.4M 1.67% 1,925,066 SH
15 SAB BIOTHERAPEUTICS INC SABS 78397T202 $31.1M 1.46% 7,967,207 SH
16 INVENTIVA SA IVA 46124U107 $30.9M 1.45% 8,163,191 SH
17 AURA BIOSCIENCES INC AURA 05153U107 $30.5M 1.44% 4,298,248 SH
18 TYRA BIOSCIENCES INC TYRA 90240B106 $25.8M 1.21% 806,986 SH
19 OPUS GENETICS INC IRD 67577R102 $25.0M 1.17% 6,077,084 SH
20 ANIKA THERAPEUTICS INC ANIK 035255108 $21.0M 0.99% 1,435,130 SH
21 SAGIMET BIOSCIENCES INC SGMT 786700104 $19.3M 0.91% 2,500,000 SH
22 ARTIVA BIOTHERAPEUTICS INC ARTV 04317A107 $16.8M 0.79% 1,736,111 SH
23 FAETH THERAPEUTICS INC FTH 81728A207 $15.7M 0.74% 629,467 SH
24 MBX BIOSCIENCES INC MBX 55287L101 $11.0M 0.52% 200,000 SH
25 VERRICA PHARMACEUTICALS INC VRCA 92511W207 $5.7M 0.27% 923,910 SH
26 AGIOS PHARMACEUTICALS INC Call AGIO 00847X104 $3.3M 0.16% 90,000 SH
27 ADMA BIOLOGICS INC Call ADMA 000899104 $2.5M 0.12% 300,000 SH
28 CELLECTAR BIOSCIENCES INC CLRB 15117F880 $1.3M 0.06% 469,998 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $2.13B 28 0001420506-26-001809
2026-03-31 2026-05-15 $1.50B 28 0001420506-26-001039
2025-12-31 2026-02-17 $1.21B 24 0001420506-26-000584
2025-09-30 2025-11-14 $763.5M 18 0001420506-25-003441
Filer Information
Address
780 THIRD AVENUE
30TH FLOOR
NEW YORK, NY 10017
Phone
(718) 570-6018
Filing Manager
Caligan Partners LP
NEW YORK, NY
Signatory
Tiffany Crowley
Chief Financial Officer/Chief Compliance Officer